1 Ocak 2021 Dergi makalesi Açık Erişim

Bolat, Zeynep Busra; Nezir, Ayca Ece; Devrim, Burcu; Zemheri, Ebru; Gulyuz, Sevgi; Ozkose, Umut Ugur; Yilmaz, Ozgur; Bozkir, Asuman; Telci, Dilek; Sahin, Fikrettin

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/229642</identifier>
  <creators>
    <creator>
      <creatorName>Bolat, Zeynep Busra</creatorName>
      <givenName>Zeynep Busra</givenName>
      <familyName>Bolat</familyName>
    </creator>
    <creator>
      <creatorName>Nezir, Ayca Ece</creatorName>
      <givenName>Ayca Ece</givenName>
      <familyName>Nezir</familyName>
      <affiliation>Yeditepe Univ, Fac Engn, Dept Genet &amp; Bioengn, TR-34755 Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Devrim, Burcu</creatorName>
      <givenName>Burcu</givenName>
      <familyName>Devrim</familyName>
      <affiliation>Ankara Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06560 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Zemheri, Ebru</creatorName>
      <givenName>Ebru</givenName>
      <familyName>Zemheri</familyName>
      <affiliation>Univ Hlth Sci, Umraniye Training &amp; Res Hosp, Dept Pathol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Gulyuz, Sevgi</creatorName>
      <givenName>Sevgi</givenName>
      <familyName>Gulyuz</familyName>
    </creator>
    <creator>
      <creatorName>Ozkose, Umut Ugur</creatorName>
      <givenName>Umut Ugur</givenName>
      <familyName>Ozkose</familyName>
    </creator>
    <creator>
      <creatorName>Yilmaz, Ozgur</creatorName>
      <givenName>Ozgur</givenName>
      <familyName>Yilmaz</familyName>
      <affiliation>TUBITAK, Mat Inst, Marmara Res Ctr, TR-41470 Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Bozkir, Asuman</creatorName>
      <givenName>Asuman</givenName>
      <familyName>Bozkir</familyName>
      <affiliation>Ankara Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06560 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Telci, Dilek</creatorName>
      <givenName>Dilek</givenName>
      <familyName>Telci</familyName>
      <affiliation>Yeditepe Univ, Fac Engn, Dept Genet &amp; Bioengn, TR-34755 Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Sahin, Fikrettin</creatorName>
      <givenName>Fikrettin</givenName>
      <familyName>Sahin</familyName>
      <affiliation>Yeditepe Univ, Fac Engn, Dept Genet &amp; Bioengn, TR-34755 Istanbul, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Delivery Of Doxorubicin Loaded P18 Conjugated-Poly (2-Ethyl-Oxazoline)-Dope Nanoliposomes For Targeted Therapy Of Breast Cancer</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2021</publicationYear>
  <dates>
    <date dateType="Issued">2021-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/229642</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.taap.2021.115671</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Breast cancer, a heterogeneous disease, has the highest incidence rate and is a major cause of death in females worldwide. Drug delivery by using nanotechnology has shown great promise for improving cancer treatment. Nanoliposomes are known to have enhanced accumulation ability in tumors due to prolonged systemic circulation. Peptide 18 (P18), a tumor homing peptide targeting keratin-1 (KRT-1), was previously shown to have high binding affinity towards breast cancer cells. In this study, we investigate the ability of P18 conjugated PEtOxDOPE nanoliposomes (P18-PEtOx-DOPE) for the targeted delivery of doxorubicin to AU565 breast cancer model. Toxicology studies of PEtOx-DOPE nanoliposomes performed on normal breast epithelial cells (MCF10A), showed minimal toxicity. Doxorubicin delivery by P18-PEtOx-DOPE to AU565 cells induces cytotoxicity in a dose and time dependent manner causing mitotic arrest in G2/M phase at 24 h. Anti-cancer activity of P18-PEtOxDOPE-DOX nanoliposomes on AU565 cells was detected by Annexin V/PI apoptosis assay. In terms of in vivo antitumor efficacy, P18-PEtOx-DOPE-DOX nanoliposomes administration to AU565 CD-1 nu/nu mice model showed significant decrease in tumor volume suggesting that DOX delivered by these nanoliposomes elicited a strong antitumor response comparable to the free delivery of doxorubicin. Overall, our results offered preclinical proof for the use of P18-PEtOx-DOPE-DOX nanoliposomes in KRT-1+ breast cancer therapy.</description>
  </descriptions>
</resource>